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Abstract
End-stage renal disease is the last stage of chronic kidney disease and affects more than 2 million patients worldwide. The infection-related hos-
pitalization is an important cause of excess morbidity and mortality in this group of patients. Yersinia enterocolitica (YE) is one of the bacteria 
that hemodialysis (HD) patients can occasionally be infected with. The most common symptoms are fever and mild diarrhea, which is self-lim-
ited. However, in HD patients, especially in iron-overloaded cases, severe watery or bloody diarrhea can occur. The consumption of undercooked 
food by patients should sensitize the physician to the possibility of YE infection. Clinically, YE is difficult to diagnose due to nonspecific symp-
toms and the relatively low prevalence of yersiniosis, compared to other causative pathogens in dialysis patients. There is little information about 
yersiniosis in HD patients. For this reason, this review aims to summarize the current knowledge on YE infection in HD patients, with the main 
objective of expounding the problems in identifying, diagnosing, and treating yersiniosis in HD patients.
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Introduction
Yersinia enterocolitica (YE) is a gram-negative bacillus that 
can cause a zoonotic disease called enteric yersiniosis. YE 
is characterized by acute diarrhea, mesenteric adenitis, ter-
minal ileitis, and appendicitis-like syndrome, which usually 
manifests as right lower quadrant abdominal pain, fever, 
vomiting, elevated white blood cells count, and diarrhea (1). 
Enteric Yersiniosis occurs more frequently in Europe 
(1.8 cases per 100,000 population) than in North Amer-
ica (0.28 per 100,000) (2, 3). However, the epidemiology of 
yersiniosis remains unclear and poorly understood (4, 5). 
Children are more exposed to the risk of complications of 
YE infection  (3). YE can cause sepsis in immunocompro-
mised patients, including those with end-stage renal disease 
(ESRD) undergoing hemodialysis (HD) (1, 6). It is well-
known that patients receiving HD have a lot of immunolog-
ical changes (7, 8). Over the past decades, extensive research 
has expanded the insights into those changes. It showed a 
decrease in lymphocytes count, significant increase of nat-
ural killer (NK) cells, with high levels of cytokine factors 
that stimulate monocyte and granulocyte production (9). 
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Immune Dysfunction in HD Patients
Infections are a major cause of  morbidity and mortality 
in dialysis patients, second only to cardiovascular disease. 
One of the major predisposing factors for susceptibility 
to infection in this group of patients is uremia-associated 
immunodeficiency. It is a dysfunction in which both immune 
activation and immune suppression coexist. Due to the 
reduction of the kidney’s clearance, uremic toxins are accu-
mulated and directly or indirectly stimulated by receptors 
on immune cells. This leads to different aspects of  inflam-
mation, including overproduction of ROS and nitrogen 
species as well as inflammatory cytokines by phagocytes, 
endothelial cells, and monocyte chemotactic stimulation 
(30–32). It is important to note that uremia-associated 
immune dysfunction in HD patients affects both innate and 
adaptive immunity (31). The innate immunity system helps 
with recognition and phagocytosis, and the induction of 
inflammation, while adaptive immunity is associated with 
the production of antibodies and memory cells. It has been 
reported that in this group of patients, their neutrophils, 
macrophages, T-lymphocytes, and B- lymphocytes undergo 
increased apoptosis (33). Such leukopenia along with the 
compromised microbicidal ability and nitric oxide synthesis 
inhibition of innate immune cells attenuate their respon-
siveness to infections. Furthermore, decreased lympho-
cytes counts and dendritic cell depletion, which break the 
messengering bridge between innate and adaptive immune 
systems in HD patients, weaken the efficiency of  both sys-
tems’ response to bacterial infections (30, 32). Interestingly, 
it is worth mentioning that contrary to the mechanisms of 
immunosuppressive conditions in HD patients, post-renal 
transplantation patients acquire infections mainly due to 
the use of  immunosuppression drugs rather than their own 
immunity level post- transplantation (34).
The Role of Iron Overload in YE Infection
Anemia is a major problem in most patients receiving 
chronic dialysis. It is characterized not only by erythropoi-
etin (EPO) deficiency but also by iron deficiency from poor 
intestinal iron absorption and low ferritin levels. Almost all 
HD patients treated with EPO receive parenteral iron (Fe) 
to ensure sufficient Fe during therapy (35–37). Intravenous 
Fe therapy helps to maintain Fe stores and decreases EPO 
demand in patients undergoing chronic HD. While it is gen-
erally believed that restoration of hemoglobin toward the 
target range is a good outcome of Fe therapy, it has been 
noticed that Fe overload and Fe toxicity may be the adverse 
consequences of this treatment (38, 39). Long-term pre-
scription of Fe can potentially lead to Fe overload, where 
it accumulates in organs such as the liver, myocardium, 
and joints (40, 41). Fe overload has been associated with 
Furthermore, it has been demonstrated that uremic toxins, 
restricted diet, hypervolemia, and hypertension can cause an 
increase in the number of reactive oxygen species (ROS).
A decrease in antioxidant defense causes disturbances in 
the intestinal barrier, resulting in the translocation of endo-
toxins (10). All factors previously mentioned clarify why 
HD patients are more prone to be infected than the general 
population. Intravenous iron and deferoxamine therapy 
also largely increase the susceptibility of HD patients to YE 
infection (11–13).
Method
Electronic and manual searches were performed in PubMed, 
Google Scholar, EMBASE, WHO guidelines, and Science 
Direct using the keywords, “hemodialysis, Yersinia enteroco-
litica, and yersiniosis.” Currently, there is no review regard-
ing this noteworthy topic of YE infection in HD patients. 
This review summarizes the current knowledge on identify-
ing, diagnosing, and treating YE infection in HD patients, 
with the principal objective of improving the understanding 
of the pathogenesis and the clinical features of yersiniosis in 
HD patients.
Yersinia enterocolitica
YE, one of  the members of  the Yersiniaceae family under 
the Enterobacteriaceae order, possesses biochemically het-
erogeneous strains, and they are classified into six bio-groups 
(1A,1B,2,3,4,5), with more than 57 O serogroups. However, 
only strains belonging to bio-groups 1B,2,3,4,5 are patho-
genic (8, 14). Serogroups are specific to different geograph-
ical areas; for example, bio-serogroups 4/O:3 and 2–3/O: 9 
are prevalent in Europe, while 2–3/O:5,27 are prevalent in 
Japan (14, 15). Temperature is crucial for YE pathogenesis. 
To infect, YE possesses some virulence factors that help it 
to colonize the intestinal tract and resist the host defense 
mechanisms; most of  them are temperature-regulated (14, 
16–20). The epidemiology of YE infection is poorly under-
stood; most sporadic cases of  yersiniosis are reported 
without apparent sources and a lack of  investigation into 
the sources of  contamination (4, 5). Large outbreaks of 
enteric yersiniosis have been reported from North Amer-
ica  (Canada), Europe (The Netherlands, Finland, Norway, 
and Germany), and Asia (Japan, Bangladesh) (21–27). 
However, among developed countries, incidences of  yersin-
iosis outbreak appeared to be lower than in less developed 
countries  (4). Several sources and routes of  YE infection 
have been identified, with meats (especially pork), raw milk, 
and fish being most commonly involved in YE transmission 
(4, 28, 29). Eating undercooked meat and drinking untreated 
water are considered to be the main causes of  acquiring 
yersiniosis (29).
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reduced phagocytic function and oxidative burst, as well 
as impaired bacterial killing (42–45). Furthermore, sev-
eral studies have also demonstrated the close relationship 
between the availability of Fe and bacterial virulence, includ-
ing YE (14, 46–48). Most bacteria acquire Fe by producing 
and releasing high-affinity chelators called siderophores that 
help to bind and solubilize ferric iron. The Fe/ siderophore 
complexes then enter bacterial cells after binding to spe-
cific receptors. Deferoxamine is a bacterial siderophore that 
is used as a chelating agent in the treatment of Fe toxicity 
or of chronic Fe overload states. YE requires Fe for growth 
and has receptors for siderophores, and it is different from 
other bacteria in that it cannot produce siderophores endog-
enously (14, 49). In Robins-Browne et al. (11), experiment 
suggested that iron dextran and deferoxamine exert an 
adverse influence on the course of experimental yersiniosis, 
and the effect of this chelating agent probably accounts in 
part for the increased susceptibility of humans with iron 
overload to systemic yersiniosis and possibly to other infec-
tions.  Abcarian et al. (12) reported that systemic YE infec-
tion occurs almost exclusively in patients with Fe overload 
treated with chelating agents. Other researchers also sug-
gest that the administration of deferoxamine against iron 
overload predisposes to YE sepsis by stimulating bacteria 
growth  (13). It is worth mentioning that iron-chelators are 
rarely used in the EPO era, but the use of EPO may help 
protect against such infection.
Incidence and Prevalence of YE Infection in 
Dialysis Units
There is little information about YE infection in dialy-
sis units. However, the available data suggest that the inci-
dence of yersiniosis in dialysis units is rare, compared to 
other causative pathogens commonly found in HD patients 
(50, 51). Most HD patients infected by YE were found to be 
overloaded with Fe (52–55). However, there is also a report 
of an HD patient infected with YE without being overloaded 
with Fe (56). Some studies have suggested that ESA therapy 
might help in the treatment of YE, as it lowers serum fer-
ritin and transferrin saturation, and improves phagocytosis 
(57–59). Septicemia due to YE infection has been reported 
sporadically. Some reported cases were associated with the 
administration of deferoxamine (60–62), and one case was 
reported due to eating undercooked meat (56). Table 1 sum-
marizes the reported YE infections in HD patients.
Nosocomial Transmission of YE Infection  
in Dialysis Units
Several studies have suggested that HD patients are most sus-
ceptible to nosocomial infections among all other hospitalized 
patients (63–65). There are reports of YE spread in hospital 
dialysis units (21, 66–68), although nosocomial transmission 
of YE infection is not a major risk for HD patients (69–71). 
Table 1: Summary of reported yersinia enterocolitica infection in hemodialysis patients.










Country Reference in 
this review 
Waterlot Y et al. 1985 ? Yes Yes Yes France 62
Boyce N et al. 1985 1 Yes Yes Yes Australia 61
Hoen B et al. 1988 1 Yes Yes Yes France 60
Hoen B et al. 1991 ? No ? Yes France 55
Gaughan WJ 
et al. 
1992 12 3 of them Varies Varies The United 
States
54
Fakir M et al. 1992 1 No Yes No France 53
Stoffel et al. 1998 1 No Yes No Germany 6
Mergenhagen 
et al. 
2011 1 No Yes Yes The United 
States
52
Intra et al. 2017 1 No Yes No Italy 56
Delicou et al. 2017 1 Yes Yes Yes Greece 79
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of the organisms could continue for weeks after the onset of 
syndromes. YE grows more slowly than Enterobacteriaceae 
and needs selective media such as Cefsulodin-irgasan-novo-
biocin (CIN) agar. Identification and bio-grouping of YE 
are performed after 48 h on the suspected colonies, and 
most results are available in 72 h (85). However, because of 
the compromised immunity of HD patients, their stool cul-
tures are rarely positive; instead, nucleic acid amplification 
test (NAAT) gastrointestinal multiplex panel (GIMP) is espe-
cially useful for this group of patients because it targets only 
pathogenic YE strains and has a faster turnaround time (86).
Serological tests
To detect IgG, IgA, and IgM antibodies, and for the diagnosis 
of YE, common serological tests like enzyme-linked immuno-
sorbent assays (ELISA) and immunoblotting have been used 
in Europe and Japan but not in the United States, because 
of the lack of guidelines to interpret agglutinin titers  (87). 
Agglutinin titers in the range of 1:128 are considered positive 
for YE infection; however, in HD patients, negative or mini-
mal titers (≥ 1:32) cannot rule out yersiniosis (88).
Imaging studies
As the pain of YE infection is localized to the right lower 
quadrant, it is easily mistaken for acute appendicitis. Ultra-
sonography and CT scan are useful in distinguishing true 
appendicitis from pseudo-appendicitis, especially in HD 
patients. CT imaging can be used to further confirm or rule 
out intrahepatic or splenic abscesses (89).
Treatment of YE in HD Patients
YE infection is a self-limiting disease in the general popula-
tion. Most of the time, patients are treated symptomatically 
with intravenous fluids in the case of severe dehydration. 
Nevertheless, HD and other immunocompromised patients 
are at a higher risk of developing septicemia; thus, they 
often require treatment with antibiotics (79). As these are 
beta-lactamase-producing bacteria, penicillin, and first- and 
second-generation cephalosporins are ineffective (1). The 
combination of doxycycline and an aminoglycoside is most 
recommended. Trimethoprim-sulfamethoxazole, fluoro-
quinolones, chloramphenicol, and third-generation cephalo-
sporins have also been proven to be effective. However, the 
choice of antibiotics and doses are largely dependent on the 
initiation time of treatment and the degree of severity of 
the  disease (90–92). In complicated gastrointestinal infec-
tions or focal extra-intestinal infections, Cover et al. (77) sug-
gested doxycycline or trimethoprim-sulfamethoxazole as an 
alternative to fluoroquinolones. Previous study had shown 
that using third-generation cephalosporins with or without 
other antibiotics; fluoroquinolones alone or with other med-
ications to be effective in the case of YE septicemia (93). 
Nosocomial transmission modes of YE are typically through 
the fecal–oral route; they occur by contact spread between 
patients, patients and healthcare workers (HCWs) (either direct 
or indirect), or through contaminated water, food, medications, 
or devices and equipment (66–68). Although the clinical signif-
icance and the contribution of YE to nosocomial transmission 
in dialysis units are unclear, it is important to strictly enforce all 
recommendations in universal precautions and HD procedures 
to prevent YE along with other gastrointestinal infections 
among all patients in dialysis units. Furthermore, a segrega-
tion policy can be considered for HD patients with severe diar-
rhea to prevent direct or indirect contact transmission (66, 72). 
 Figure 1 summarizes the nosocomial transmission routes and 
the prevention of YE infection in dialysis units (73–76).
Clinical Presentations and Outcomes of YE 
Infection in HD Patients
Under most circumstances, YE infection presents with 
enterocolitis, mild fever, and pseudo-appendicitis. How-
ever, HD patients have high-grade fever (up to 40°C), chills, 
severe abdominal pain, watery or bloody diarrhea, and some 
extra-intestinal manifestations, such as lymphadenitis, ery-
thema nodosum, reactive arthritis, uveitis, and septicemia, 
due to their compromised immunity, especially in those 
treated with deferoxamine (6, 61, 77–79). Clinically, it is 
not easy to distinguish infections of YE from that of other 
enteric pathogens. However, if  the patient has diarrhea for 
several days with the pain localized to the right lower quad-
rant, and has a recent history of consuming undercooked 
food, especially pork, soft cheese, or unpasteurized milk, 
YE involvement has to be suspected. In this case, laboratory 
tests along with computed tomography (CT) imaging can 
be used to confirm the diagnosis. Although reactive arthri-
tis, erythema nodosum, liver and splenic abscess are major 
complications of YE infection (78, 80), currently there are no 
reports on the natural histological progress regarding com-
plications of YE infection in HD patients.
Diagnostic Approaches for YE Complications
There are no specific chemical, radiological, or hematologi-
cal findings that can confirm the diagnosis of YE infection 
in HD patients. Multiple approaches are preferred for diag-
nosis, which can be established by culture isolation from the 
stool, mesenteric lymph nodes, peritoneal fluid or blood (in 
case of sepsis), or through CT scan and ultrasonography 
(81, 82). Nevertheless, there are some special considerations 
in the use and interpretation of the results in HD patients.
Stool culture
In case of digestive disorders, stool culture is the best way to 
confirm the diagnosis of YE (83, 84), as the stool shedding 
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1. Clean patients’s room,
    bed and besides
    equipment thoroughly
2. Limit the transport of
    hospitalized patient
    with infectious diarrhea
1. HCW effective hand-
    washing before and
    after touching patients
2. Wear gloves /gowns
3. HCW comply with
    personal hygiene
1. Segregation
    policy
2. Avoid frequent
    exchange of
    patients and
    hospital staff
    among affected
    wards
1. Thoroughly wash
    unprocessed
    vegetables and
    fruits
2. Avoid the use of
    multi-dose vials
    (to prevent
    development of
    drug-resistent
    bacteria)
3. Prepare and serve
    foods with clean
    utensils
4. Avoid serving
    undercooked
    pork, soft cheese
    or unpasteurized
    milk to patients
5. Sterilize or boil the
    drinking water for












Figure 1: The nosocomial transmission routes and prevention of Yersinia enterocolitica infection in dialysis units. YE: Yersinia 
Enterocolitica; HCW: healthcare workers.
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Hemodialysis patients
Several days of diarrhea





Supportive care or antibiotic treatment (doxycycline or
chloramphenicol, combine or alone), depends on the
severity patient
Start antibiotics treatment as soon as possible
−> Recommend using third generation cephalosporins
alone or in combination with fluoroquinolones or
   trimethoprim-sulfamethoxazole with reduced dose
−> Avoid gentamicin in patients with residual diuresis




Suggest using at least 2 methods mentioned below, with one of it being NAAT or
culture test to confirm the diagnosis:
1. NAAT test or culture from stool, mesenteric lymph nodes, blood
2. Serological tests such as ELISA, immnuoblotting
3. Imaging studies (CT scan, ultrasonagraphy)
If patient has conditions mention below:
  1. Iron overloaded
  2. Recent history of consuming undercooked food
  3. Mild to high fever without any other known reasons
  4. Pain localized to right lower quadrant
  5. Has been treated with deferoxamine recently
Figure 2: Suggested algorithm for the management of Yersinia enterocolitica infection in hemodialysis patients. YE: Yersinia 
enterocolitica; NAAT: nucleic acid amplification test; CT: computed tomography; ELISA: enzyme-linked immunosorbent assay.
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Evol Microbiol. 2016;66(12):5575–99. http://dx.doi.org/10.1099/
ijsem.0.001485
15. Leon-Velarde CG, Happonen L, Pajunen M, Leskinen K, 
Kropinski AM, Mattinen L. Yersinia enterocolitica-specific 
infection by bacteriophages TG1 and φR1-RT is dependent on 
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dx.doi.org/10.1128/AEM.01594-16
16. Marceau M. Transcriptional regulation in Yersinia: An update. 
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17. Straley SC, Perry RD. Environmental modulation of 
gene expression and pathogenesis in Yersinia. Trends 
Microbiol. 1995 Aug;3(8):310–17. http://dx.doi.org/10.1016/
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Temperature-dependent regulation of Yersinia enterocolitica 
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19. Bengoechea JA. Regulation of O-antigen biosynthesis in 
Yersinia enterocolitica. Adv Exp Med Biol. 2003;529:267–74. 
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Tauxe et al. (93) recommended YE septicemia patients being 
treated with intravenous third-generation cephalosporin such 
as ceftriaxone or ciprofloxacin (2 g per day in adults or 100 
mg/kg per day in pediatric group, with the maximum dose of 
4 g/day) along with gentamicin (5 mg/kg per day divided into 
one to three doses). As gentamicin can cause further neph-
rotoxicity in HD patients with residual diuresis, we recom-
mend administering third-generation cephalosporins alone 
or in combination with fluoroquinolones or a reduced dose 
of trimethoprim-sulfamethoxazole for YE septicemia HD 
patients. For nonsepticemia, YE-infected HD patients with 
severe enterocolitis and extra-intestinal disorders, we rec-
ommend doxycycline or chloramphenicol either alone or in 
combination, depending on the severity. A suggested algo-
rithm for the management of YE infection in HD patients is 
summarized in Figure 2.
Conclusion
YE infection is not commonly diagnosed in HD patients. 
However, in HD patients with an iron overload, having 
severe watery or bloody diarrhea for several days, especially 
with the recent consumption of undercooked food, should 
alert physicians to the possibility of YE infection. Stool cul-
ture or NAAT along with imaging tests (ultrasonography or 
CT scan) are recommended to confirm the diagnosis. Differ-
ential diagnosis should be made between appendicitis and 
liver or splenic abscess. In septicemia, antibiotic treatment 
with third-generation cephalosporins alone or in combina-
tion with fluoroquinolones or trimethoprim-sulfamethoxaz-
ole are recommended. For non-septicemia YE-infected HD 
adult patients with severe enterocolitis and extra-intestinal 
disorders, we recommend using doxycycline. Further studies 
of YE infection in HD patients may provide new methods of 
yersiniosis treatment for this group of patients.
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